Expression of histone H2AX phosphorylation and its potential to modulate adriamycin resistance in K562/A02 cell line

Abstract

DNA repair processes play a role in the development of drug resistance which represents a huge obstacle to leukemia chemotherapy. Histone H2AX phosphorylation (ser139) (γH2AX) occurs rapidly at the onset of DNA double strand break (DSB) and is critical to the regulation of DSB repair. If DNA repair is successful, cells exposed to anti-neoplastic drugs will keep entering the cycle and develop resistance to the drugs. In this study, we investigated whether γH2AX can be used as an indicator of tumor chemosensitivity and a potential target for enhancing chemotherapy. K562 and multi-drug resistant cell line K562/A02 were exposed to adriamycin (ADR) and γH2AX formed. Flow cytometry revealed that percentage of cells expressing γH2AX was increased in a dose-dependent manner and the percentage of K562/A02 cells was lower than that of K562 cells when treated with the same concentration of ADR. In order to test the potential of γH2AX to reverse drug resistance, K562/A02 cells were treated with PI3K inhibitor LY294002. It was found that LY249002 decreased ADR-induced γH2AX expression and increased the sensitivity of K562/A02 cells to ADR. Additionally, the single-cell gel electrophoresis assay and the Western blotting showed that LY249002 enhanced DSBs and decreased the expression of repair factor BRCA1. These results illustrate chemosensitivity can partly be measured by detecting γH2AX and drug resistance can be reversed by inhibiting γH2AX.

Keywords

γH2AX / DNA DSBs / LY249002 / K562/A02 cells / drug resistance

References

[1] HendersonM.J., ChoiS., BeesleyA.H., et al.. Mechanism of relapse in pediatric acute lymphoblastic leukemia. Cell Cycle, 2008, 7(10): 1315-1320

[2] SrivastavaN., GochhaitS., de BoerP., et al.. Role of H2AX in DNA damage response and human cancers. Mutat Res, 2009, 681(2–3): 180-188

[3] PaullT.T., RogakouE.P., YamazakiV., et al.. A critical role for histone H2AX in recruitment of repair factors to nuclear foci after DNA damage. Curr Bio, 2000, 10(15): 886-895

[4] TanejaN., DavisM., ChoyJ.S., et al.. Histone H2AX phosphorylation as a predictor of radiosensitivity and target for radiotherapy. J Biol Chem, 2004, 279(3): 2273-2280

[5] BassingC.H., ChuaK.F., SekiguchiJ., et al.. Increased ionizing radiation sensitivity and genomic instability in the absence of histone H2AX. Proc Natl Acad Sci USA, 2002, 99(12): 8173-8178

[6] BanáthJ.P., MacphailS.H., OliveP.L.. Radiation sensitivity, H2AX phosphorylation, and kinetics of repair of DNA strand breaks in irradiated cervical cancer cell lines. Cancer Res, 2004, 64(19): 7144-7149

[7] ClingenP.H., WuJ.Y., MillerJ., et al.. Histone H2AX phosphorylation as a molecular pharmacological marker for DNA interstrand crosslink cancer chemotherapy. Biochem Pharmacol, 2008, 76(1): 19-27

[8] HuangX., OkafujiM., TraganosF., et al.. Assessment of histone H2AX phosphorylation induced by DNA topoismerase I and II inhibitors topotecan and mitoxantrone and by the DNA cross-linking agent cisplatin. Cytometry A, 2004, 58(2): 99-110

[9] KuroseA., TanakaT., HuangX., et al.. Effects of hydroxyurea and aphidicolin on phosphoacylation of ataxia telangiectasia mutated on Ser1981 and histone H2AX on Ser 139 in relation to cell cycle phase and induction of apoptosis. Cytometry A, 2006, 69(4): 212-221

[10] ZhuH., HuangM., YangF., et al.. R16, a novel amonafide analogue, induces apoptosis and G2-M arrest via poisoning topoisomerase II. Mol Cancer Ther, 2007, 6(2): 484-495

[11] ZijlstraJ.G., de VriesE.G., MulderN.H.. Multifactorial drug resistance in an adriamycin-resistant human small cell lung carcinoma cell line. Cancer Res, 1987, 47(7): 1780-1784

[12] CelesteA., Fernandez-CapetilloO., KruhlakM.J., et al.. Histone H2AX phosphorylation is dispensable for the initial recognition of DNA breaks. Nat Cell Biol, 2003, 5(7): 675-679

[13] SarkariaJ.N., TibbettsR.S., BusbyE.C., et al.. Inhibition of phosphoinositide 3-kinase related kinases by the radiosensitizing agent wortmannin. Cancer Res, 1998, 58(19): 4375-4382

[14] FuhrmanC.B., KilgoreJ., LaCoursiereY.D., et al.. Radiosensitization of cervical cancer cells via double-strand DNA break repair inhibition. Gynecol Oncol, 2008, 110(1): 93-98

[15] SinghN.P., McCoyM.T., TiceR.R., et al.. A simple technique for quantitation of low levels of DNA damage in individual cells. Exp Cell Res, 1988, 175: 184-191

[16] Fernandez-CapetilloO., LeeA., NussenzweigM., et al.. H2AX: the histone guardian of the genome. DNA Repair Amst, 2004, 3(8-9): 959-967

[17] BanathJ.P., OliveP.L.. Expression of phosphorylated histone H2AX as a surrogate of cell killing by drugs that create DNA double-strand breaks. Cancer Res, 2003, 63(15): 4347-4350

[18] OliveP.L., BanathJ.P., SinnottL.T.. Phosphorylated histone H2AX in spheroids, tumors, and tissues of mice exposed to etoposide and 3-amino-1, 2, 4-benzotriazine-1, 3-dioxide. Cancer Res, 2004, 64(15): 5363-5369

[19] CowellI.G., DurkaczB.W., TilbyM.J.. Sensitization of breast carcinoma cells to ionizing radiation by small molecule inhibitors of DNA-dependent protein kinase and ataxia telangiectsia mutated. Biochem Pharmacol, 2005, 71(1–2): 13-20

[20] AuW.W., HendersonB.R.. Identification of sequences that target BRCA1 to nuclear foci following alkylative DNA damage. Cell Signal, 2007, 19(9): 1879-1892

[21] ZhaoY., ThomasH.D., BateyM.A., et al.. Preclinical evaluation of a potent novel DNA-dependent protein kinase inhibitor NU7441. Cancer Res, 2006, 66(10): 5354-5362

[22] WillmoreE., ElliottS.L., MainouF.T., et al.. DNA-dependent protein kinase is a therapeutic target and an indicator of poor prognosis in B-cell chronic lymphocytic leukemia. Clin Cancer Res, 2008, 14(12): 3984-3992